Feb 13, 2025 · We hypothesized that modifying our CD70 CAR platform to secrete a bispecific T-cell engaging antibody molecule (TEAM) targeting CD33 (70 33) would create a therapeutic …

Feb 10, 2023 · Given the fact that combinatorial antigenic targeting approaches are being explored for potential improved antitumor activity compared to conventional CAR T-cells, we …

Jan 16, 2025 · Scientists believe they have identified a way to circumvent the antigen heterogeneity that has challenged chimeric antigen receptor (CAR) T cell treatment in the …

Nov 5, 2024 · MP0533 is a tetra-specific CD3-engaging DARPin (Designed Ankyrin Repeat Protein) that simultaneously targets CD33, CD123, and CD70, leading to avidity-driven T cell …

Jan 2, 2025 · In an animal model, CD33 CAR-NK cells demonstrated increased antileukemia efficacy, comparable to that of CD33 CAR-T-cell therapy. We designed a phase I clinical trial …

Nov 5, 2024 · To prevent fratricide in CAR-Ts, which express both aITGB2 and CD70 when activated, we optimized a CRISPR-Cas9 protocol using a library of guide RNAs to knock out …

Feb 13, 2025 · We hypothesized that modifying our CD70 CAR platform to secrete a bispecific T-cell engaging antibody molecule (TEAM) targeting CD33 (7033) would create a therapeutic …

We detected the CD70 expression on the surfaces of AML cell lines, primary AML cells, HSC, and peripheral blood cells and generated a second-generation CD70-specific CAR-T cells using a …

Nov 22, 2024 · CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML

Jul 2, 2024 · We designed MP0533, a multispecific CD3-engaging designed ankyrin repeat protein (DARPin) that can simultaneously bind to three antigens on AML cells (CD33, CD123, …